A randomized controlled trial of 286 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) tested a three-arm intervention over 18 months. Patients receiving the full "Co-Co-Nut" protocol — combining hepatologist oversight, individualized nutrition, and cognitive behavioral therapy (CBT) — achieved significantly greater rates of ≥10% body weight loss, with sustained improvements in liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and metabolic markers compared to standard care (all p < 0.0001). Most strikingly, the multidisciplinary group showed a 64% reduction in acute cardiovascular events (HR 0.36, 95% CI 0.18–0.71), and 12-month adherence independently predicted cardiovascular risk reduction (HR 0.27).
This trial addresses one of the most stubborn problems in hepatology and metabolic medicine: patients know what to do but cannot sustain it. By weaving CBT into MASLD management, the intervention targets the behavioral architecture of adherence rather than just prescribing diet and exercise. The cardiovascular effect size is remarkable — larger than most pharmacological trials in this population — though the open-label design and single-center Italian cohort limit immediate generalizability. The identification of social determinants of adherence failure (large families, time constraints, full-time employment) adds practical granularity clinicians can actually use. If replicated in diverse populations, this model could reframe fatty liver management as a behavioral-medical integration challenge rather than a pharmacological one — a genuinely paradigm-adjacent finding for the field.